STOCK TITAN

Vanguard files 13G/A: NeoGenomics (NEO) ownership shows 0 shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

NeoGenomics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of NeoGenomics common stock following an internal realignment.

The filing explains subsidiaries and business divisions of The Vanguard Group now report separately in reliance on SEC Release No. 34-39538, and Vanguard states it holds 0% of the class.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; Vanguard reports no beneficial ownership in NeoGenomics.

The amendment states The Vanguard Group underwent an internal realignment and that certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The filing records 0 shares and 0% ownership of NeoGenomics common stock.

Cash‑flow treatment and specific subsidiary counts are not included in the excerpt; subsequent separate filings by Vanguard affiliates may show redistributed positions.






64049M209

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What did The Vanguard Group report for NEO in this Schedule 13G/A?

The Vanguard Group reported 0 shares beneficially owned of NeoGenomics common stock and stated a 0% ownership position, following an internal organizational realignment.

Why does Vanguard say it now reports holdings separately for NEO?

Vanguard states an internal realignment on January 12, 2026 caused certain subsidiaries or business divisions to report disaggregated holdings in reliance on SEC Release No. 34-39538 and to report separately from The Vanguard Group, Inc.

Does this filing show any voting or dispositive power over NEO shares?

No. The filing lists 0 shares for sole voting power, shared voting power, sole dispositive power, and shared dispositive power, indicating no reported control of NeoGenomics shares.

Will NeoGenomics shareholders see immediate changes from this 13G/A filing?

This amendment is an ownership reporting change: it records Vanguard's disaggregation and 0% ownership; it does not itself alter NeoGenomics operations or governance as disclosed in the excerpt.

Who signed the Schedule 13G/A amendment for Vanguard on NEO?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with signature date 03/27/2026, certifying the reported ownership information.
Neogenomics Inc

NASDAQ:NEO

View NEO Stock Overview

NEO Rankings

NEO Latest News

NEO Latest SEC Filings

NEO Stock Data

1.01B
128.02M
Diagnostics & Research
Services-testing Laboratories
Link
United States
FORT MYERS